Radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-based hapten (Radiolabeled DOTA-hapten)

A radiolabeled DOTA-based hapten is a small molecule complex consisting of a DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator, a radioisotope, and often a peptide linker. It is a critical component of pretargeted radioimmunotherapy (PRIT) and pretargeted imaging strategies, rather than a biological target itself (Cheal et al., 2016, Mol. Cancer Ther.). In these systems, the hapten is designed to be recognized with high affinity by a bispecific antibody that has already localized to a tumor-associated antigen (Bodet-Milin et al., 2016, Front. Med.). This two-step process decouples the slow pharmacokinetics of large antibodies from the fast pharmacokinetics of small radiolabeled molecules. By doing so, it allows for high tumor-to-background ratios, enhancing the therapeutic index of radionuclides like Lutetium-177 or Actinium-225 (Schoffelen et al., 2014, J. Nucl. Med.). This technology is primarily investigated for the treatment and imaging of various cancers, including colorectal and breast malignancies, where it aims to deliver potent radiation while sparing healthy tissues like the bone marrow.

Other names

DOTA-haptenRadiolabeled DOTA-chelateDOTA-based radioligandMetal-DOTA haptenDOTA-peptide hapten

The radiolabeled DOTA-based hapten acts as a secondary effector molecule in a multi-step pretargeting system. It binds with high affinity to the capture arm of a pre-localized bispecific antibody at the tumor site, delivering a radioactive payload for imaging or therapy while ensuring rapid systemic clearance of non-targeted molecules (Cheal et al., 2016, Mol. Cancer Ther.).